Abstract. Charcot-Marie-Tooth disease (CMT) is a clinically and genetically heterogeneous peripheral neuropathy. The objective of this study was to find the causative mutation(s) in a demyelinating autosomal dominant CMT family. A high density SNP-based genome-wide linkage scan was performed, and causative mutations were determined by sequencing of candidate genes in the linkage disequilibrium region. Linkage analysis mapped the underlying gene to a region on chromosome 1q22-q23 with a maximum two-point LOD score of 2.036. Sequencing analysis revealed a novel c.243C>G (His81Gln) mutation in the MPZ gene, which encodes the major integral membrane protein of the peripheral nerve system. MPZ is well known as a CMT-causative gene with wide phenotypic spectrum. The clinical symptoms were more similar to those of patients with the His81Arg than patients with the His81Tyr mutation. The novel mutation completely co-segregated with affected members, and was not found in controls. Therefore, we suggest that the identified mutation in MPZ is the underlying cause of CMT in the family. In addition, this study demonstrated that the clinical phenotypes may be variable with different mutations at the same site in the MPZ gene.

Introduction

Hereditary motor and sensory neuropathy (HMSN), also called Charcot-Marie-Tooth disease (CMT), is a genetically and clinically heterogeneous disorder of the peripheral nervous system with a predominance of approximately 1 in 2500 people. CMT patients usually exhibit clinical symptoms of muscle weakness, sensory loss and foot deformities. CMT is classically divided into two types, the demyelinating type (CMT1) and the axonal type (CMT2), based on electrophysiological criteria. The demyelinating type has reduced median motor nerve conduction velocities (NCVs) (<38 m/sec), whereas the axonal type has slightly reduced or normal NCVs (>38 m/sec) (1,2). A major reason for demyelination is glial dysfunction, which is responsible for malformation or destruction of the myelin sheath (3,4). Demyelinating peripheral neuropathies usually ultimately lead to impaired function and degeneration of axons (5,6).

The most frequent autosomal dominant demyelinating subtype is the CMT1A genomic disorder (MIM# 118220), which is relevant with recurrent or non-recurrent rearrangements of chromosome 17p12 including the MPZ22 gene (MIM# 601097) (7-12). The CMT1B (MIM# 118200) is the second most frequent autosomal dominant demyelinating subtype, and is relevant with MPZ (P0) gene (MIM# 159440) mutations (13). However, MPZ mutations are also associated with other phenotypes, including severe Dejerine-Sottas syndrome (DSS, MIM# 145900) and axonal CMT, such as CMT2I (MIM# 607677) and CMT2J (MIM# 607736). These variable clinical phenotypes are usually associated with specific MPZ mutations, namely different phenotypes by different mutation sites. Moreover, some MPZ mutations have shown considerable clinical heterogeneity in the affected individuals not only among families, but also within the same family (14,15).

To date, more than 50 genes or loci have been reported to be associated with CMT or related diseases at the Inherited Peripheral Neuropathies Mutation Database (IPNMD) (http://www.molgen.ua.ac.be/CMTMutations/Mutations/) and in other reports. Genotype-phenotype correlations are occasionally less strict in CMT patients, and CMT displays clinically wide phenotypic heterogeneity according to causative mutation sites within a same gene. These factors make it difficult to
predict specific genetic defects from several dozen causative genes. Therefore, narrowing chromosomal co-segregation region by the genome-wide linkage scan and subsequent sequencing analysis of a restricted number of candidate genes may be a more effective route rather than direct screening of all the CMT causative genes.

Two different mutations at the 81st amino acid site (His81) in the MPZ gene have been reported from CMT patients with different phenotypes: His81Arg in early-onset severe CMT1 (16,17) and His81Tyr in late-onset mild CMT2 (18). In the present study, we identified another novel MPZ His81 mutation (His81Gln) in a Korean early-onset autosomal dominant demyelinating CMT family. For identification of the causative mutation, a high density SNP-based genome-wide linkage study and sequencing for the candidate genes were performed.

**Material and methods**

**Subjects.** This study included a total of 23 members (7 affected and 16 unaffected individuals) of a Korean early-onset autosomal dominant CMT1 family (family ID: FC133) (Fig. 1A). The paternity was confirmed by genotyping of 15 microsatellite markers using a PowerPlex 16 kit (Promega, Madison, WI). In addition, this study included 120 healthy controls who had no clinical features of neuromuscular disorder. Total DNA was extracted from the whole peripheral blood samples using a QIAGen DNA Blood mini kit (Qiagen, Hilden, Germany). All participants in this study provided written informed consent, and the study was approved by the Ethics Committee of Ewha Womans University, Mokdong Hospital.

**Genome-wide linkage studies.** A high density SNP-based genome-wide linkage scan was performed on 16 familial members by applying the Infinium II HumanLinkage-12 Panel (Illumina, San Diego, CA), to identify the linkage disequilibrium region. The chip included 6,090 SNP markers that are uniformly distributed on every chromosome with an average gap of 441 kb (approximately 0.58 cM interval). Genotyping data were scanned by the Illumina BeadStation 500G array scanner, and analyzed with the Merlin-1.1.2 software using the autosomal dominant parametric model. SNP positions were obtained from the UCSC hg18 at the UCSC Genome Browser (http://genome.ucsc.edu/) or Build 36.1 at the NCBI website (http://blast.ncbi.nlm.nih.gov/).

**Mutation screening.** Sequencing analysis of all coding exons and flanking intronic sequences was performed on several candidate genes in the linkage disequilibrium region (1q22-q23), and in several other CMT genes. We also examined the 1.4 Mb duplication/deletion on 17.12 by the method of Choi et al (11). The primer sequences and the PCR conditions are available upon request. Sequencing reactions were performed using a BigDye Terminator v3.1 Cycle Sequencing kit, and sequences were then determined on an automatic genetic analyzer ABI 3100 (Applied Biosystems, Foster City, CA). Sequence variations were identified by the SeqScape (v.2.1, Applied Biosystems) and Chromas software (v.2.33, Technelysium, Australia). We confirmed the sequence variations by analyzing both strands of DNA. Multiple alignments of amino acid sequences among different species were performed with the ClustalX v.1.83 program.

**Clinical assessment.** Patients were evaluated by obtaining a detailed history including motor and sensory impairments, deep tendon reflexes, and muscle atrophy. Muscle strengths of flexor and extensor muscles were assessed manually using the standard medical research council (MRC) scale. In order to determine the physical disability we used two scales, the functional disability scale (FDS) (19) and the CMT neuropathy score (CMTNS) (20). Disease severity was determined for each patient using a nine-point FDS, which was based on the following criteria: 0, normal; 1, normal but with cramps and fatigability; 2, an inability to run; 3, walking difficulty but still possible to walk unaided; 4, walking with a cane; 5, walking with crutches; 6, walking with a walker; 7, wheelchair bound; and 8, bedridden. Additionally, patients were divided into mild (CMTNS ≤10), moderate (CMTNS, 11-20), and severe (CMTNS ≥21) categories. Sensory impairments were assessed in terms of the level and severity of pain, temperature, vibration, and position, and pain and vibration senses were compared.

**Electrophysiological examination.** Nerve conduction studies were tested with a surface electrode in median, ulnar, peroneal, tibial, and sural nerves. Motor nerve conduction velocities (MNCVs) of the median and ulnar nerves were determined by stimulation at the elbow and wrist while recording compound muscle action potentials (CMAPs) over the abductor pollicis brevis and adductor digitii quinti, respectively. Sensory nerve conduction velocities (SNCVs) were obtained over a finger-wrist segment from the median and ulnar nerves by orthodromic scoring, and were also recorded for sural nerves.

**MRI study.** Among the 7 affected patients, MRI was performed on 5 male patients (II-18, 20, IV-13, 14 and 17). Two patients did not receive an MRI assessment because of being too young (IV-16, 3 years and IV-18, 5 years). MRI was performed on the lumbar spine and lower legs in a supine position using a Siemens 1.5T vision system (Siemens, Erlangen, Germany) equipped with a phase-array multicoil. Lower leg imaging was carried out in the axial [field of view (FOV) 24-32 cm, slice thickness 10 mm, and slice gap 0.5-1.0 mm] and coronal planes (FOV 38-40 cm, slice thickness 4-5 mm, slice gap 0.5-1.0 mm). The following protocol was used for the 5 patients: T1-weighted spin-echo (SE) (TR/TE 570-650/14-20, 512 matrixes), T2-weighted SE (TR/TE 2800-4000/96-99, 512 matrixes), and fat-suppressed T2-weighted SE (TR/TE 3090-4900/85-99, 512 matrixes) in both planes.

**Histopathological study.** The pathological examination of the proband (III-20) included light and electron microscopic analyses of the distal sural nerve. A fragment of peripheral nerve fiber was received in a fresh state. Formalin fixed sections with hematoxylin-eosin, modified Masson’s trichrome, Luxol fast blue and Bodian stains were examined.
For the electron microscopic observations, the specimens were fixed in 2% glutaraldehyde in 0.025 M cacodylate buffer pH 7.4, and processed for semithin and ultrathin sections. Semithin sections stained with toluidine blue were prepared for evaluation using light microscopy. Ultrathin cut samples (60-65 nm) were contrasted with uranyl acetate and lead citrate for an ultrastructural study (H-7650, Hitachi, Japan). The density of the myelinated fibers (MFs), the axonal diameter and myelin thickness, and the g-ratio of MFs (axon diameter/total fiber diameter) were assessed directly from the toluidine blue-stained semithin transverse sections of the sural nerve using a computer-assisted image analyzer (analySIS®, Soft Imaging System, GmbH, Germany). The numbers of MFs with thick myelin or folding, thin myelinated axons, onion bulbs surrounding MFs, and regenerative clusters or axon sprouts (consisting of two or more adjacent myelinated axons surrounded by flattened Schwann cell processes) were assessed with electron microscopy at a lower magnification (x3,000). Unmyelinated fiber density was assessed from electron microscopic photographs at x10,000 magnification, taken to randomly cover uranyl acetate-stained ultrathin transverse sections.

Results

Identification of a linkage disequilibrium region on 1q22-q23. The genome-wide SNP scan revealed two candidate regions of linkage disequilibrium co-segregating with affected members, chromosome 1q22-q23 spanning from approximately 130-168 cM and 8p12-8q11.2 spanning from approximately 55-65 cM (Fig. 1B). The maximum obtained LOD scores were 2.036 at the SNP markers rs954679-rs1935745 (1q22-q23), and 2.035 at rs1000236-rs185596 (8p12-8q11.2) in the autosomal dominant inheritance model (theta =0.00).

The 1q22-q23 linkage disequilibrium region included two genes relevant with CMT, MPZ and LMNA. For the 8p12-8q11.2 region, no CMT-causative gene was reported; however, NEFL (8p21.2) and GDAP1 (8q21.1) genes were located on some distant vicinity of the disequilibrium region. The linkage study excluded several important CMT loci: 1p36.2 (MFN2), 10q21.2 (EGR2), 17p12 (PMP22), 19q13.2 (PRX) and Xq13.1 (GJB1).

Identification of a novel missense mutation in MPZ. From the screening of the candidate genes on the 1q22-q23 linkage disequilibrium region, a missense change in exon 3 of MPZ on 1q23.3 was identified as a functionally significant variant. The mutation was a C>G transversion at position 243 (c.243C>G), which leads to substitution of a histidine residue with glutamine, His81Gln (Fig. 2A). This mutation completely co-segregated with all affected members in the pedigree FC133 (III-18, III-20, IV-13, IV-14, IV-16, IV-17 and IV-18). Sequencing analysis confirmed the absence of this mutation in unaffected members of the pedigree and in 240 ethnically matched healthy control chromosomes. The His81 mutation site is located on the extracellular immunoglobulin-like domain of the MPZ protein, and is highly conserved among other species (Fig. 2B). The c.243C>G mutation has not been reported in the dbSNP database (http://www.ncbi.nlm.nih.gov/snp/) or the Inherited Peripheral Neuropathies Mutation Database (http://www.molgen.ua.ac.be/CMTMutations/Mutations/). However, two different mutations have been reported at the same His81...
Sequencing analysis of LMNA on 1q22, NEFL and GDAP1 on chromosome 8 revealed no causative mutation. Although we excluded most CMT loci by the linkage study, mutational screening was performed for several other CMT genes. However, we could not find any causative mutation from the following genes: GJB1 (Cx32), EGR2, GARS, HSP22, HSP27, PMP22, PRX and YARS. In addition, 1.4 Mb duplication/deletion on 17p12 was also excluded by genotyping of 6 microsatellites.

Clinical manifestations. The clinical features of the 7 patients (5 males, 2 females) are outlined in Table I. Muscle weakness and atrophy were first noted and predominated in the distal portions of the upper and lower limbs, and paresis in the distal regions varied from minimal to severe. Mean age at onset was 5.0±2.7 years (range 2-9 years) and disease duration at the time of examination was 12.9±14.4 years (range 1-36 years). Length-dependent sensory loss was found in 6 patients (86%). Vibration sense was reduced to a greater extent than pain in 2 of the 5 patients, while in 3 patients it was reduced to a similar extent. Mean FDS was 2.1±1.1 (range 1-4 years) and CMTNS was 15.4±7.3 (range 7-27 years). Two patients were in the severe category (CMTNS >21), and 5 of the 7 patients were in the mild to moderate category (CMTNS ≤20). Pes cavus and ataxia were found in 6 patients (86%), and postural hand tremor in 2 patients (29%). The pupils of the proband were symmetric (3 mm) with absent light reflex and very slow near reaction and miosis in response to instillation of 0.1% pilocarpine. Pupil findings were identical to the patient’s brother (III-18), son (IV-17), and cousins (IV-13 and -14). They did not have strabismus or ptosis. There was no evidence of either toxic habits or systemic disease, which could contribute to the observed neuropathy or papillary syndrome.

Electrophysiological findings. Neurophysiologic studies were carried out in all the affected individuals. MNCVs of median, ulnar, peroneal and tibial nerves, and SNCVs of median, ulnar and sural nerves are shown in Table II. The nerve conduction study demonstrated markedly reduced MNCVs, and the range of median MNCV was from 6.2-14.9 m/sec, and that of CMAP was from 0.1-3.8 mV. In patient (III-18), the amplitudes of evoked motor responses were markedly reduced, and we were unable to record amplitudes. All patients, except one with absent MNCVs, had at least one motor NCV <38 m/sec. Sensory NCVs between finger and wrist were not recordable in all affected patients.

MRI findings. Among the 5 patients for whom MR images were obtained, all patients revealed grade I or II fatty infiltrations of both legs. Fatty infiltration was noted along the anterior and lateral compartment of both legs in a symmetric fashion. Fatty infiltration was greater in the III-18 and III-20 subjects (Fig. 3A and B) than in the IV-13, IV-14 and IV-17 (Fig. 3C-E), which indicates that fatty infiltration is related to disease duration. MRI features of the thigh were almost normal in all patients. These findings are similar to the reported features of demyelinating CMT1A neuropathy (21,22).
Histopathological features. Semithin transverse sections showed severe loss of MFs of all calibers and the remaining MFs could be barely counted 412/mm$^2$ (normal distal sural nerve in 45-year-old female: 7,300/mm$^2$ or 8,190±511 (Fig. 4A) (23). Abnormally MFs with thick myelin (or folding) (24.2%, 100/mm$^2$), thin myelinated axons (6.1%, 25/mm$^2$), onion bulbs surrounding MFs (42.4%, 175/mm$^2$), and regenerative clusters or axon sprouts (12.1%, 50/mm$^2$) were observed. The histogram showed a unimodal distribution pattern with an axonal diameter >8 µm comprising 12.1% of MFs, and MFs <3 µm were absent (Fig. 4B). The range of the diameter and the average diameter of MFs were 3.4-11.0 and 5.7 µm, respectively (normal distal sural nerve in 45-year-old female, 1.8-14.8 and 5.4 µm). The MF% area in this case was 1.1% (normal distal sural nerve of 45-year-old female, 26.9%). The range of the g-ratio was 0.6-0.8 (normal distal sural nerve of 42-year-old male, 0.6-0.7) (23). A g-ratio >0.7 comprised 60.6% of MFs and none of the fibers showed a g-ratio <0.4. Electron microscopic examination revealed onion bulbs surrounding myelinated and unmyelinated fibers and axon sprouts (Fig. 4C), abnormally MFs with excessive myelin outfoldings or focally folded myelin exhibiting degenerative

Table II. Electrophysiological features in 7 affected individuals with MPZ mutation.

<table>
<thead>
<tr>
<th>Patient</th>
<th>Age at exam</th>
<th>Side</th>
<th>Motor nerve conduction study</th>
<th>Sensory nerve conduction study</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>Median</td>
<td>Ulnar</td>
</tr>
<tr>
<td>III-18</td>
<td>44</td>
<td>Right</td>
<td>NR</td>
<td>NR</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Left</td>
<td>NR</td>
<td>14.9 (0.3)</td>
</tr>
<tr>
<td>III-20</td>
<td>40</td>
<td>Right</td>
<td>12.2 (0.1)</td>
<td>13.5 (3.3)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Left</td>
<td>11.0 (3.7)</td>
<td>7.4 (5.5)</td>
</tr>
<tr>
<td>IV-13</td>
<td>10</td>
<td>Right</td>
<td>9.1 (2.6)</td>
<td>7.2 (8.1)</td>
</tr>
<tr>
<td></td>
<td>12</td>
<td>Left</td>
<td>11.5 (3.8)</td>
<td>8.0 (3.0)</td>
</tr>
<tr>
<td>IV-14</td>
<td>8</td>
<td>Right</td>
<td>8.2 (1.8)</td>
<td>5.7 (4.4)</td>
</tr>
<tr>
<td></td>
<td>3</td>
<td>Right</td>
<td>6.2 (0.1)</td>
<td>4.5 (0.4)</td>
</tr>
<tr>
<td>IV-17</td>
<td>13</td>
<td>Right</td>
<td>11.9 (2.1)</td>
<td>9.2 (4.0)</td>
</tr>
<tr>
<td></td>
<td>5</td>
<td>Right</td>
<td>9.2 (1.7)</td>
<td>8.9 (3.0)</td>
</tr>
</tbody>
</table>

$^{a,b}$Amplitudes of the evoked responses are given in parentheses [in mV for motor nerve conduction velocities (NCVs) and in µV for sensory NCVs]. Normal motor NCV values: median nerve ≥50.5 m/sec; ulnar nerve ≥51.1 m/sec; tibial nerve ≥41.1 m/sec; normal sensory NCV values: median nerve ≥39.3 m/sec; ulnar nerve ≥37.5 m/sec; sural nerve ≥32.1 m/sec. Normal amplitude values: motor median nerve ≥6 mV; ulnar nerve ≥8 mV; tibial nerve ≥6 mV; sensory median nerve ≥8.8 µV; sensory ulnar nerve ≥7.9 µV; sural nerve ≥6.0 µV. Nr, not recordable.
changes (Fig. 4D), uncompacted myelin, and thinly myelinated axons (Fig. 4E). Compared with MFs, the unmyelinated fibers were relatively well preserved and were counted as 65,763/mm² (control, 28,400/mm² or 29,913±3,457) (23). Endoneurial fibroblast proliferation and large amounts of collagen deposition have been well documented.

Discussion

We identified two linkage disequilibrium regions on chromosome 1q22-q23 and 8p12-8q11.2 in the FC133 autosomal dominant CMT1 family by the genome-wide SNP linkage study. Sequencing analysis revealed a novel c.243C>G
(His81Gln) transversion mutation in the MPZ gene, which encodes a major component of myelin of the peripheral nerve system. Our data support that the His81Gln mutation in the MPZ is responsible for the autosomal dominant demyelinating CMT in family FC133 due to the following reasons: i) co-segregation of the mutation with affected members in the pedigree, ii) no detection of the same mutation in 240 ethnicity matched control chromosomes, iii) high conservation of amino acids at the mutation site among different species, iv) absence of alternative causative mutations in known CMT genes and v) close matching of the phenotype with the MPZ mutations.

MPZ encodes a 29 kDa transmembrane glycoprotein, which is the major structural protein of peripheral myelin. Expression of MPZ is restricted to Schwann cells, and plays a role in linking adjacent lamellae and thereby stabilizing the myelin assembly. MPZ protein belongs to the immunoglobulin supergene family, and contains three domains: an extracellular domain, a transmembrane domain and an intracellular C terminal domain (24,25). After Bird et al. mapped the autosomal dominant CMT1B locus on 1q22-q23 (26), Hayasaka et al. identified the MPZ mutations as the underlying cause of CMT1B (13). To date, more than a hundred MPZ mutations have been reported to be relevant with cMT. Mutations in MPZ are shown to be responsible for a wide range of cMT phenotypes from mild to severe and from early-onset to late-onset (27-29). In particular, the marked phenotypic variations on the same MPZ mutation suggest other putative modifying gene(s) (14,15).

The His81Gln mutation locates on the extracellular immunoglobulin-like domain. The extracellular domain plays an important role in myelin compaction, and most CMT-causative mutations are localized within the extracellular domain. In particular, the His81 residue has been suggested to influence the adhesion interface between homotypic interactions (30). Although His81Gln has not been previously reported, two mutations have been reported in the His81 site. His81Arg has been described in early-onset CMT1 patients (16,17). Notably, a Japanese female patient with the mutation exhibited severe CMT1 with bilateral trigeminal thickening and an abnormality of the auditory brain stem response (17). The mutation of His81Tyr has been identified to be concurrent with another heterozygous mutation, Val113Phe, in a late-onset CMT female with axonal neuropathy and pupillary light-near dissociation (18). The symptoms were less severe than for patients having His81Arg. In our case, the family FC133 showed the typical CMT1 phenotype similarly to the patients with His81Arg. The clinical features showed demyelinating CMT1 neuropathies in His81Arg and His81Gln; however, His81Tyr displayed axonal CMT2 neuropathy. A sural nerve pathological finding with His81Tyr showed mainly axonal neuropathy with only a few onion bulbs; however, the present 40-year-old male revealed features of demyelinating neuropathy such as frequent onion bulb formations (42.4%) as well as MFs with thick myelin or folding (24.2%) and thin myelinated axons (6.1%). In addition, on the MRI, the patients with the MPZ mutation showed grade I-II fatty infiltration along the anterolateral compartment of the lower leg, similarly to the reported feature of CMT1A neuropathy (21,22). It is interesting that variable phenotypes were observed even among subjects with mutations at the same

<table>
<thead>
<tr>
<th>Amino acid change</th>
<th>Median NCV (m/sec)</th>
<th>Severity</th>
<th>Area at onset (years)</th>
<th>Main phenotype</th>
<th>Pathological findings</th>
<th>Leg MR1 findings</th>
<th>Other phenotypes</th>
</tr>
</thead>
<tbody>
<tr>
<td>His81Gln</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Mild-to-severe</td>
<td>2-9</td>
<td>CMT1</td>
<td>Frequent onion bulbs (42%)</td>
<td>Anterolateral compartments involved</td>
<td>Adie's pupil, ataxia, tremor</td>
</tr>
<tr>
<td>His81Arg</td>
<td></td>
<td>Mild</td>
<td>2-9</td>
<td>CMT1</td>
<td>Frequent onion bulbs (11% )</td>
<td>Anterolateral compartments involved</td>
<td>Trigeminal nerve thickening</td>
</tr>
<tr>
<td>His81Arg</td>
<td></td>
<td>Severe</td>
<td>2-9</td>
<td>CMT1/DSS</td>
<td>No onion bulbs</td>
<td>Anterolateral compartments involved</td>
<td>Bilateral trigeminal thickening</td>
</tr>
<tr>
<td>His81Tyr + Val113Phe</td>
<td></td>
<td>Mild</td>
<td>35</td>
<td>CMT2</td>
<td>35.0</td>
<td>Only a few onion bulbs</td>
<td>Light-near dissociation</td>
</tr>
</tbody>
</table>

The mean median nerve motor conduction velocity of affected family members. DSS, Dejerine-Sottas syndrome; MNCV, motor nerve conduction velocity; SNCV, sensory nerve conduction velocity; ND, no description; NR, not recordable.
site of the MPZ (Table III). In a similar case, two Pro22 mutations in NEFL genes revealed different phenotypes: Pro22Ser in CMT2E and Pro22Thr in CMT1F (31).

According to the present study, the novel MPZ mutation appears to be the causative mutation for the CMT disease in the CMT1 family. We also found that the clinical phenotypes may vary even among different mutations at the same site in the MPZ gene.

Acknowledgements

This study was supported by the Mid-career Researcher Program through an NRF grant funded by the MEST (R01-2008-000-20604-0), the Korea Healthcare Technology R&D Project, Ministry for Health, Welfare and Family Affairs (A0905000), Republic of Korea.

References
